Skip to content Skip to footer
Subscribe Now
CXO TALKS

CXO Talks Podcast | The Road to Acquisition: Oncolytics’ CEO Jared Kelly on Clinical Data, IP & Pharma Partnerships

What does it really take for a biotech company to become an attractive acquisition target? In this episode of PharmaShots CXO Talks, Jared Kelly, CEO & Director of Oncolytics Biotech, shares an insider's perspective shaped by years of experience in biotech transactions, corporate strategy, and business development. Before joining Oncolytics, Kelly served as Head of…
June 24, 2026

Read more

VIEWPOINTS

Roy Maute on Macrophage Checkpoint Inhibition: Pheast’s Vision for Advancing PHST001 in Solid Tumors 

Shots:  Pheast Therapeutics is redefining innate immunity in oncology with PHST001, an anti-CD24 macrophage checkpoint inhibitor engineered to overcome the limitations of earlier macrophage-targeted therapies and unleash a powerful anti-tumor immune response.  At AACR 2026, PHST001 delivered encouraging early clinical signals with favorable tolerability, clear immune activation, and promising anti-tumor responses across heavily pretreated solid tumor…
May 27, 2026

Read more